Having already attracted more than USD 1bn of venture capital and other sources of funding, CRISPR – a breakthrough technology in gene editing – is revolutionizing biotechnology. Big pharma, chemical and seed companies have recently signed licensing agreements to develop CRISPR for a range of medical, agricultural and industrial applications.